Health-related quality of life in the CDC Anthrax Vaccine Adsorbed Human Clinical Trial

Stewart, Brock; Rose, Charles E.; Tokars, Jerome I.; Martin, Stacey W.; Keitel, Wendy A.; Keyserling, Harry L.; Babcock, Janiine; Parker, Scott; Jacobson, Robert M.; McNeil, Michael M.

doi:10.1016/j.vaccine.2012.06.076

Cited by 5 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In studies from the Vaccine Analytic Unit and other groups published since 2010, no association was found between AVA receipt and the following chronic health conditions: reduction in health-related quality of life measures ( 46 ), multisystem illness ( 47 ), long-term disabilities ( 48 , 49 ), type 1 diabetes ( 50 ), atrial fibrillation ( 51 ), and diffuse connective tissue diseases ( 52 ). In one case-control study, an association was identified between AVA receipt and new-onset rheumatoid arthritis if a look-back period of 3 months was used (odds ratio [OR]: 3.93; 95% CI: 1.08–14.27).…”

Section: Summary Of Key Findingsmentioning

confidence: 99%

Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019

Bower

Schiffer²,

Atmar³

et al. 2019

MMWR Recomm. Rep.

Self Cite

View full text Add to dashboard Cite

This report updates the 2009 recommendations from the CDC Advisory Committee on Immunization Practices (ACIP) regarding use of anthrax vaccine in the United States (Wright JG, Quinn CP, Shadomy S, Messonnier N. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices [ACIP)], 2009. MMWR Recomm Rep 2010;59[No. RR-6]). The report 1) summarizes data on estimated efficacy in humans using a correlates of protection model and safety data published since the last ACIP review, 2) provides updated guidance for use of anthrax vaccine adsorbed (AVA) for preexposure prophylaxis (PrEP) and in conjunction with antimicrobials for postexposure prophylaxis (PEP), 3) provides updated guidance regarding PrEP vaccination of emergency and other responders, 4) summarizes the available data on an investigational anthrax vaccine (AV7909), and 5) discusses the use of anthrax antitoxins for PEP. Changes from previous guidance in this report include the following: 1) a booster dose of AVA for PrEP can be given every 3 years instead of annually to persons not at high risk for exposure to Bacillus anthracis who have previously received the initial AVA 3-dose priming and 2-dose booster series and want to maintain protection; 2) during a large-scale emergency response, AVA for PEP can be administered using an intramuscular route if the subcutaneous route of administration poses significant materiel, personnel, or clinical challenges that might delay or preclude vaccination; 3) recommendations on dose-sparing AVA PEP regimens if the anthrax vaccine supply is insufficient to vaccinate all potentially exposed persons; and 4) clarification on the duration of antimicrobial therapy when used in conjunction with vaccine for PEP.These updated recommendations can be used by health care providers and guide emergency preparedness officials and planners who are developing plans to provide anthrax vaccine, including preparations for a wide-area aerosol release of B. anthracis spores. The recommendations also provide guidance on dose-sparing options, if needed, to extend the supply of vaccine to increase the number of persons receiving PEP in a mass casualty event.

show abstract

Section: Summary Of Key Findingsmentioning

confidence: 99%

Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019

Bower

Schiffer²,

Atmar³

et al. 2019

MMWR Recomm. Rep.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Data from the UK and US suggest that anthrax vaccination prevents disease . Anthrax vaccination is considered safe . Injection site reactions occur in 47% of AVP recipients .…”

Section: Anthraxmentioning

confidence: 99%

British HIV Association Guidelines on the Use of Vaccines in HIV‐Positive Adults 2015

et al. 2016

View full text Add to dashboard Cite

Anthrax Vaccines *

Friedlander¹,

Grabenstein²,

Brachman³

2018

Plotkin's Vaccines

View full text Add to dashboard Cite

Health-related quality of life in the CDC Anthrax Vaccine Adsorbed Human Clinical Trial

Abstract: These results do not favor an association between receipt of AVA and an altered health-related quality of life over a 42-month period.

Cited by 5 publications

References 14 publications

Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019

Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019

British HIV Association Guidelines on the Use of Vaccines in HIV‐Positive Adults 2015

Anthrax Vaccines *

Contact Info

Product

Resources

About